Aeolian Biotech is reaching for an improved pneumococcal vaccine. Our management team includes senior leaders of the intitial Prevnar team at Wyeth and Pfizer. Our iPCV project, based on issued IP exclusively licensed to Aeolian by our founders, will provide protection against 95% of serotypes causing invasive disease in US adults. We have raised seed funding and are now seeking Series A funds that would support the company to clinical proof of concept data, estimated to be available 24 months after close of the Series A round.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):